← 홈

Antibody · 고형암 (전체)

287개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 287개
AntibodystaleZhongda HospitalPreclinical

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab)

Hepatocellular Carcinoma · PD-1

#PD-1#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystalePfizerPhase 1

nivolumab (Opdivo, TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Nivolumab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystalePfizerPhase 1

PF-07901800 (TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Rituximab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleJiangsu HengruiPhase 2

PVE+cTACE+Camrelizumab+Apatinib (PVE+cTACE+Camrelizumab+Apatinib)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, PXS-5505 and Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma; Cancer of Liver · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleDana-Farber Cancer InstitutePhase 2

Pembroluzimab (Pembroluzimab)

HPV-positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma · HPV-positive Oropharyngeal Squamous Cell

#HPV-positiveOropharyngealSquamou#Antibody#Phase2#항체#면역항체+3
효능 ORR 0.0%임상시험 1상태 RECRUITING
AntibodystaleEastern Hepatobiliary Surgery H…Phase 2

durvalumab (Imfinzi, Pemigatinib and Durvalumab)

Biliary Tract Carcinoma; Cholangiocarcinoma · Biliary Tract Carcinoma

#BiliaryTractCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleGenelux CorporationPhase 2

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Ovarian Cancer; Peritoneal Carcinomatosis · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 80%임상시험 1상태 ACTIVE
AntibodystaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 1

RAD001, Cetuximab, Irinotecan (RAD001, Cetuximab, Irinotecan)

Colorectal Cancer; Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRegeneronPhase 2

REGN15505+Cemiplimab (REGN15505+Cemiplimab)

Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) · Metastatic Castration-Resistant Prostate

#MetastaticCastration-ResistantPr#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengRui Medicine Co., L…Phase 3

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+3
효능 ORR 28.8%임상시험 1상태 ACTIVE
AntibodystaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#항체#면역항체+5
효능 ORR 42%임상시험 1상태 ACTIVE
AntibodystaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#항체#면역항체+3
효능 ORR 21%임상시험 1상태 ACTIVE

11 / 15 페이지

← 이전다음 →